

## Nucala® (mepolizumab) - New formulation approval

- On June 6, 2019, <u>GlaxoSmithKline announced</u> the FDA approval of <u>Nucala (mepolizumab)</u> single-dose prefilled autoinjector and single-dose prefilled syringe, for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype; and treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
  - Nucala is not indicated for the relief of acute bronchospasm or status asthmaticus.
- Nucala autoinjector and single-dose prefilled syringe may be administered under the guidance of a healthcare provider. Both formulations allow for self-administration or administration by a patient caregiver after the healthcare provider determines it is appropriate.
  - This is the first interleukin-5 antagonist approved for at-home administration.
- Nucala was previously approved as a lyophilized powder in a single-dose vial for reconstitution.
  - Nucala vials for injection require reconstitution and administration by a healthcare professional.
- Warnings and precautions of Nucala include hypersensitivity reactions, acute asthma symptoms or deteriorating disease, opportunistic infections (ie, herpes zoster), reduction of corticosteroid dosage, and parasitic (helminth) infection.
- The most common adverse reactions (≥ 5%) with Nucala use were headache, injection site reaction, back pain, and fatigue.
- The recommended dosage of Nucala for severe asthma is 100 mg administered once every 4 weeks by subcutaneous (SC) injection into the upper arm, thigh, or abdomen.
- The recommended dosage of Nucala for EGPA is 300 mg administered once every 4 weeks by SC injection as 3 separate 100-mg injections into the upper arm, thigh, or abdomen. It is recommended that the individual 100-mg injections be administered at least 5 cm (approximately 2 inches) apart if more than 1 injection is administered at the same site.
- GlaxoSmithKline plans to launch the prefilled autoinjector and single-dose prefilled syringe formulations of Nucala shortly. Both the autoinjector and prefilled syringe will be available in a 100 mg strength.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.